Observational studyDigestive diseases and sciences2017
Cost of Illness in Inflammatory Bowel Disease.
Observational study in Digestive diseases and sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Work Productivity Impairment in Persons with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.Journal of Crohn's & colitis · 2024Pooled it
- Review
- Confronting the hidden cost of diagnostic delay in diagnosis and treatment initiation: Inflammatory bowel disease as model to understand chronic diseases.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Article
- Economic burden borne by patients due to diagnostic delays in inflammatory bowel disease: Insights from a survey of newly diagnosed patients.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Observational
- Developing IBD counsellors in low- and middle-income countries: bridging gaps in patient care.EClinicalMedicine · 2025Review
- Cost-of-illness analysis of ulcerative colitis patients treated with biological therapy: a prospective observational study in Iran.BMC health services research · 2025Observational
- Inflammatory bowel disease in south Asia: a scoping review.The lancet. Gastroenterology & hepatology · 2025Article
- Bolstering connectedness through peer support: Randomized-controlled trial of a web-based peer support program for adolescents with inflammatory bowel disease.Health care transitions · 2025Article
- Enhancing self-management of patients with inflammatory bowel disease: the role of autonomy support in health goal pursuit.Therapeutic advances in gastroenterology · 2024Article
- Economic impact of inflammatory bowel disease in Catalonia: a population-based analysis.Therapeutic advances in gastroenterology · 2024Article
- Inflammatory bowel disease: a narrative review of disease evolution in South Asia and India over the last decade.Therapeutic advances in gastroenterology · 2024Review
- The Role of Adipose Tissue Mesenchymal Stem Cells in Colonic Anastomosis Healing in Inflammatory Bowel Disease: Experimental Study in Rats.Journal of clinical medicine · 2023Article
- Tofacitinib in Steroid-Refractory Acute Severe Ulcerative Colitis: A Retrospective Analysis.Cureus · 2023Article
- Economic Burden of Inflammatory Bowel Disease in Shiraz, Iran.Archives of Iranian medicine · 2023Article
- Work-Related Productivity Loss and Associated Indirect Costs in Patients With Crohn's Disease or Ulcerative Colitis in the United States.Crohn's & colitis 360 · 2022Article
- Crohn's disease in low and lower-middle income countries: A scoping review.World journal of gastroenterology · 2020Article
- Inflammatory Bowel Disease Reoperation Rate Has Decreased Over Time If Corrected by Prevalence.Clinical and translational gastroenterology · 2020Article
- Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis: results from a nationwide study in Sweden.Alimentary pharmacology & therapeutics · 2020Article
- Rehospitalization rates, costs, and risk factors for inflammatory bowel disease: a 16-year nationwide study.Therapeutic advances in gastroenterology · 2020Article
- Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience.United European gastroenterology journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFrequent relapses sometimes necessitating hospitalization and the absence of pharmacological cure contribute to substantial healthcare costs in inflammatory bowel diseases (IBDs). The costs of health care in Indian patients with IBD are unknown.
aimTo evaluate the annual costs for treating Crohn's disease and ulcerative colitis.
methodsA prevalence-based, micro-costing method was used to assess the components of annual costs in a prospective, observational study conducted in a tertiary healthcare center enrolled over a 24-month period beginning of July 2014.
resultsAt enrollment, 43/59 (72.88%) patients with UC and 18/25 (72%) with CD were in remission. The annual median (IQR) cost per UC and CD patient in remission was INR 43,140 (34,357-51,031) [USD $707 (563-836)] and INR 43,763.5 (32,202-57,372) [USD $717 (527-940)], respectively, and in active disease was INR 52,436.5 (49,229-67,567.75) [$859 (807-1107)] and INR 72,145 (49,447-92,212) [USD $1182 (811-1512)], respectively. Compared with remission, active disease had a 1.4-fold higher cost for CD as compared to UC. In both groups, the greatest component of direct costs was drugs. Thirteen (22%) and 7 (28%) patients with UC and CD needed hospitalization accounting for 23.1 and 20.4% of the total costs, respectively. At one year, direct costs surmounted indirect costs in UC and CD (p < 0.001). Productivity losses contributed to 18.5 and 16% of the overall costs for UC and CD, respectively.
conclusionThis first, panoptic, health economic study for IBD from India shows that the costs are driven by medication, productivity losses, and not merely hospitalization alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.